These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 34214123)

  • 1. Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study.
    Kim WY; Kweon OJ; Cha MJ; Baek MS; Choi SH
    PLoS One; 2021; 16(7):e0254167. PubMed ID: 34214123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients.
    Spadaro S; Fogagnolo A; Campo G; Zucchetti O; Verri M; Ottaviani I; Tunstall T; Grasso S; Scaramuzzo V; Murgolo F; Marangoni E; Vieceli Dalla Sega F; Fortini F; Pavasini R; Rizzo P; Ferrari R; Papi A; Volta CA; Contoli M
    Crit Care; 2021 Feb; 25(1):74. PubMed ID: 33608030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy.
    Palomo M; Youssef L; Ramos A; Torramade-Moix S; Moreno-Castaño AB; Martinez-Sanchez J; Bonastre L; Pino M; Gomez-Ramirez P; Martin L; Garcia Mateos E; Sanchez P; Fernandez S; Crovetto F; Escolar G; Carreras E; Castro P; Gratacos E; Crispi F; Diaz-Ricart M
    Am J Obstet Gynecol; 2022 Aug; 227(2):277.e1-277.e16. PubMed ID: 35351411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study.
    Bhatraju PK; Morrell ED; Zelnick L; Sathe NA; Chai XY; Sakr SS; Sahi SK; Sader A; Lum DM; Liu T; Koetje N; Garay A; Barnes E; Lawson J; Cromer G; Bray MK; Pipavath S; Kestenbaum BR; Liles WC; Fink SL; West TE; Evans L; Mikacenic C; Wurfel MM
    Crit Care; 2021 Apr; 25(1):148. PubMed ID: 33874973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone.
    Butcher L; Zaldua JC; Carnicero JA; Hawkins K; Whitley J; Mothukuri R; Evans PA; Morris K; Pillai S; Erusalimsky JD
    Respir Res; 2022 Nov; 23(1):303. PubMed ID: 36335329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxemic Patients With Bilateral Infiltrates Treated With High-Flow Nasal Cannula Present a Similar Pattern of Biomarkers of Inflammation and Injury to Acute Respiratory Distress Syndrome Patients.
    García-de-Acilu M; Marin-Corral J; Vázquez A; Ruano L; Magret M; Ferrer R; Masclans JR; Roca O
    Crit Care Med; 2017 Nov; 45(11):1845-1853. PubMed ID: 28806218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.
    Mühlemann B; Thibeault C; Hillus D; Helbig ET; Lippert LJ; Tober-Lau P; Schwarz T; Müller MA; ; Witzenrath M; Suttorp N; Sander LE; Drosten C; Jones TC; Corman VM; Kurth F
    Clin Microbiol Infect; 2021 Oct; 27(10):1520.e7-1520.e10. PubMed ID: 34139335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.
    Alipanah-Lechner N; Hurst-Hopf J; Delucchi K; Swigart L; Willmore A; LaCombe B; Dewar R; Lane HC; Lallemand P; Liu KD; Esserman L; Matthay MA; Calfee CS;
    Crit Care; 2024 Feb; 28(1):56. PubMed ID: 38383504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Viremia is Associated With Inflammatory, But Not Cardiovascular Biomarkers, in Patients Hospitalized for COVID-19.
    Myhre PL; Prebensen C; Jonassen CM; Berdal JE; Omland T
    J Am Heart Assoc; 2021 May; 10(9):e019756. PubMed ID: 33596668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study.
    Vecchié A; Batticciotto A; Tangianu F; Bonaventura A; Pennella B; Abenante A; Corso R; Grazioli S; Mumoli N; Para O; Maresca AM; Dalla Gasperina D; Dentali F
    Intern Emerg Med; 2021 Oct; 16(7):1913-1919. PubMed ID: 34275096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Biomarker Analysis in Pediatric ARDS: Generating Future Framework from a Pilot Randomized Control Trial of Methylprednisolone: A Framework for Identifying Plasma Biomarkers Related to Clinical Outcomes in Pediatric ARDS.
    Kimura D; Saravia J; Rovnaghi CR; Meduri GU; Schwingshackl A; Cormier SA; Anand KJ
    Front Pediatr; 2016; 4():31. PubMed ID: 27066464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High levels of soluble VEGF receptor 1 early after trauma are associated with shock, sympathoadrenal activation, glycocalyx degradation and inflammation in severely injured patients: a prospective study.
    Ostrowski SR; Sørensen AM; Windeløv NA; Perner A; Welling KL; Wanscher M; Larsen CF; Johansson PI
    Scand J Trauma Resusc Emerg Med; 2012 Apr; 20():27. PubMed ID: 22490186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
    Tomazini BM; Maia IS; Cavalcanti AB; Berwanger O; Rosa RG; Veiga VC; Avezum A; Lopes RD; Bueno FR; Silva MVAO; Baldassare FP; Costa ELV; Moura RAB; Honorato MO; Costa AN; Damiani LP; Lisboa T; Kawano-Dourado L; Zampieri FG; Olivato GB; Righy C; Amendola CP; Roepke RML; Freitas DHM; Forte DN; Freitas FGR; Fernandes CCF; Melro LMG; Junior GFS; Morais DC; Zung S; Machado FR; Azevedo LCP;
    JAMA; 2020 Oct; 324(13):1307-1316. PubMed ID: 32876695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial).
    Arenas M; Algara M; De Febrer G; Rubio C; Sanz X; de la Casa MA; Vasco C; Marín J; Fernández-Letón P; Villar J; Torres-Royo L; Villares P; Membrive I; Acosta J; López-Cano M; Araguas P; Quera J; Rodríguez-Tomás F; Montero A
    Strahlenther Onkol; 2021 Nov; 197(11):1010-1020. PubMed ID: 34230996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts outcome of patients admitted to an ICU with COVID-19.
    Zhang D; Li L; Chen Y; Ma J; Yang Y; Aodeng S; Cui Q; Wen K; Xiao M; Xie J; Xu Y; Li Y
    Mol Med; 2021 Dec; 27(1):151. PubMed ID: 34861818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial.
    Abdolahi N; Kaheh E; Golsha R; Khodabakhshi B; Norouzi A; Khandashpoor M; Besharat S; Tavassoli S; Livani S; Azimi SA; Gharib MH; Peivandi B; Fazel A; Shirzad-Aski H; Roshandel G
    Trials; 2020 Jun; 21(1):549. PubMed ID: 32560745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of endothelial cell activation are associated with the severity of pulmonary disease in COVID-19.
    Osburn WO; Smith K; Yanek L; Amat-Alcaron N; Thiemann DR; Cox AL; Leucker TM; Lowenstein CJ
    PLoS One; 2022; 17(5):e0268296. PubMed ID: 35588115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.